NEWS RELEASE NuOncology Labs Inc Symbol: NLAB Trades: OTC BB July 9, l998 NUONCOLOGY LABS COMPLETES ACQUISITION Virginia Beach, VA - NuOncology Labs, Inc. (OTC BB: NLAB), a Florida Corporation, announced today that it has acquired all the outstanding and issued shares of NuOncology Labs, Inc. (Nulab), a private Virginia Corporation. The new combined entity will maintain the name NuOncology Labs Inc. NuOncology Labs, Inc's Senior Medical Director is R. Michael Williams, Ph.D, the co-founder, Senior Medical Director and Chief Medical Officer of Cancer Treatment Centers of America. The company's Scientific Director is Fraser S. Baker, Ph. D., co- founder and Director of Baker-Sanger Laboratory, Inc., a Houston based chemosensitivity testing laboratory. NuOncology Labs, Inc. participates in the multi- billion dollar cancer treatment industry by supporting the research and marketing of a promising cancer treatment along with the delivery of predictive tests for the optimization of contemporary cancer treatment. Both activities could greatly improve clinical outcomes while reducing treatment costs. NuOncology Labs Inc has a "dramatically effective cancer treatment" in trials with over 200 patients at this time. This project as well as NuOncology Labs Inc is being lead by a "very distinguished research and management team". To receive a complete investor package on NuOncology Labs Inc, as well as a FREE subscription to our newsletter that profiles specially selected companies in the "New Economy" we feel have the potential for tremendous growth potential PLEASE CLICK HERE: Free Info Please note that by sending an e-mail to this address you are requesting additional information on NuOncology Labs Inc as well as a FREE no obligation subscription to our newsletter. You may unsubscribe at any time. We profile these companies at the time they initially go public - before they have been discovered by 'the Street' and financial media and already doubled or tripled in price. end.